Vincristine sulfate liposomal injection for acute lymphoblastic leukemia

Trisha A. Soosay Raj, Amanda M. Smith, Andrew S. Moore

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


Vincristine (VCR) is one of the most extensively used cytotoxic compounds in hemato-oncology. VCR is particularly important for the treatment of acute lymphoblastic leukemia (ALL), a disease that accounts for approximately one-third of all childhood cancer diagnoses. VCR's full therapeutic potential has been limited by dose-limiting neurotoxicity, classically resulting in autonomic and peripheral sensory-motor neuropathy. In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies. Promising data from recent clinical trials investigating VSLI in adults with ALL resulted in US Food and Drug Administration approval for use in patients with Philadelphia chromosome (t[9;22]/BCR-ABL1) (Ph)-negative (Ph-) disease. Additional clinical trials of VSLI in adults and children with both Ph-positive (Ph+) and Ph- ALL are ongoing. Here we review the preclinical and clinical experience to date with VSLI for ALL.

Original languageEnglish
Pages (from-to)4361-4369
Number of pages9
JournalInternational Journal of Nanomedicine
StatePublished - Nov 6 2013


  • Acute lymphoblastic leukemia
  • Chemotherapy
  • Liposomes
  • Sphingosomal vincristine
  • Vincristine sulfate liposomal injection


Dive into the research topics of 'Vincristine sulfate liposomal injection for acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this